Search

Your search keyword '"Ruan, Anming"' showing total 18 results
Start Over Author "Ruan, Anming"
18 results on '"Ruan, Anming"'

4. Supplementary Figure 5 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Author

Chen, Xuanyu, primary, Wang, Xuegang, primary, Ruan, Anming, primary, Han, Weiwei, primary, Zhao, Yan, primary, Lu, Xing, primary, Xiao, Pei, primary, Shi, Hangchuan, primary, Wang, Rong, primary, Chen, Li, primary, Chen, Shaoyong, primary, Du, Quansheng, primary, Yang, Hongmei, primary, and Zhang, Xiaoping, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 4 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Author

Chen, Xuanyu, primary, Wang, Xuegang, primary, Ruan, Anming, primary, Han, Weiwei, primary, Zhao, Yan, primary, Lu, Xing, primary, Xiao, Pei, primary, Shi, Hangchuan, primary, Wang, Rong, primary, Chen, Li, primary, Chen, Shaoyong, primary, Du, Quansheng, primary, Yang, Hongmei, primary, and Zhang, Xiaoping, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 2 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Author

Chen, Xuanyu, primary, Wang, Xuegang, primary, Ruan, Anming, primary, Han, Weiwei, primary, Zhao, Yan, primary, Lu, Xing, primary, Xiao, Pei, primary, Shi, Hangchuan, primary, Wang, Rong, primary, Chen, Li, primary, Chen, Shaoyong, primary, Du, Quansheng, primary, Yang, Hongmei, primary, and Zhang, Xiaoping, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Table 2 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Author

Chen, Xuanyu, primary, Wang, Xuegang, primary, Ruan, Anming, primary, Han, Weiwei, primary, Zhao, Yan, primary, Lu, Xing, primary, Xiao, Pei, primary, Shi, Hangchuan, primary, Wang, Rong, primary, Chen, Li, primary, Chen, Shaoyong, primary, Du, Quansheng, primary, Yang, Hongmei, primary, and Zhang, Xiaoping, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Methods, Figure Legends from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Author

Chen, Xuanyu, primary, Wang, Xuegang, primary, Ruan, Anming, primary, Han, Weiwei, primary, Zhao, Yan, primary, Lu, Xing, primary, Xiao, Pei, primary, Shi, Hangchuan, primary, Wang, Rong, primary, Chen, Li, primary, Chen, Shaoyong, primary, Du, Quansheng, primary, Yang, Hongmei, primary, and Zhang, Xiaoping, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 1 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Author

Chen, Xuanyu, primary, Wang, Xuegang, primary, Ruan, Anming, primary, Han, Weiwei, primary, Zhao, Yan, primary, Lu, Xing, primary, Xiao, Pei, primary, Shi, Hangchuan, primary, Wang, Rong, primary, Chen, Li, primary, Chen, Shaoyong, primary, Du, Quansheng, primary, Yang, Hongmei, primary, and Zhang, Xiaoping, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 1 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Author

Chen, Xuanyu, primary, Wang, Xuegang, primary, Ruan, Anming, primary, Han, Weiwei, primary, Zhao, Yan, primary, Lu, Xing, primary, Xiao, Pei, primary, Shi, Hangchuan, primary, Wang, Rong, primary, Chen, Li, primary, Chen, Shaoyong, primary, Du, Quansheng, primary, Yang, Hongmei, primary, and Zhang, Xiaoping, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 3 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Author

Chen, Xuanyu, primary, Wang, Xuegang, primary, Ruan, Anming, primary, Han, Weiwei, primary, Zhao, Yan, primary, Lu, Xing, primary, Xiao, Pei, primary, Shi, Hangchuan, primary, Wang, Rong, primary, Chen, Li, primary, Chen, Shaoyong, primary, Du, Quansheng, primary, Yang, Hongmei, primary, and Zhang, Xiaoping, primary

Published
2023
Full Text
View/download PDF

14. miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma

Author

Wang, Xuegang, primary, Chen, Xuanyu, additional, Han, Weiwei, additional, Ruan, Anming, additional, Chen, Li, additional, Wang, Rong, additional, Xu, Zhenghong, additional, Xiao, Pei, additional, Lu, Xing, additional, Zhao, Yan, additional, Zhou, Jia, additional, Chen, Shaoyong, additional, Du, Quansheng, additional, Yang, Hongmei, additional, and Zhang, Xiaoping, additional

Published
2015
Full Text
View/download PDF

15. miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Author

Chen, Xuanyu, primary, Wang, Xuegang, additional, Ruan, Anming, additional, Han, Weiwei, additional, Zhao, Yan, additional, Lu, Xing, additional, Xiao, Pei, additional, Shi, Hangchuan, additional, Wang, Rong, additional, Chen, Li, additional, Chen, Shaoyong, additional, Du, Quansheng, additional, Yang, Hongmei, additional, and Zhang, Xiaoping, additional

Published
2014
Full Text
View/download PDF

18. Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation.

Author

Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, Wang R, Chen L, Han W, Ruan A, Du Q, Olumi AF, and Zhang X

Subjects
Antigens, Polyomavirus Transforming pharmacology, Apoptosis, Cell Line, Dose-Response Relationship, Drug, Epithelial Cells pathology, Gene Expression Regulation, Humans, Male, Marine Toxins, Okadaic Acid pharmacology, Oxazoles pharmacology, Phenotype, Protein Phosphatase 2 metabolism, RNA, Small Interfering pharmacology, TNF-Related Apoptosis-Inducing Ligand genetics, TNF-Related Apoptosis-Inducing Ligand metabolism, Telomerase, Cell Transformation, Neoplastic, Enzyme Inhibitors pharmacology, Epithelial Cells metabolism, Protein Phosphatase 2 antagonists & inhibitors
Abstract

Unlabelled: TRAIL is a promising anticancer agent because it induces apoptosis in the majority of human cancer cells but spares the normal cells. To determine the mechanistic nature of how normal cells acquire a TRAIL-sensitive phenotype during the process of malignant transformation, an experimental cell system was developed by sequential introduction of human telomerase reverse transcriptase and SV40 T antigens (large and small) into normal human prostatic epithelial cells (PrEC). This model system demonstrated that inhibition of protein phosphatase 2A (PP2A), either by SV40 small T antigen, okadaic acid, Calyculin A, or PP2A catalytic subunit siRNA, sensitized normal human PrEC and immortalized cells to TRAIL-induced apoptosis. Moreover, sensitization occurred during the premalignant period of tumorigenesis and PP2A exerted its antiapoptotic activity by negatively regulating c-Fos/AP-1. In addition, low-dose okadaic acid treatment sensitized TRAIL-resistant cancer cells to TRAIL, suggesting that PP2A inhibitors could be used as an enhancer of apoptosis induced by TRAIL or TRAIL-like agents. These data indicate that downregulation of PP2A activity is a critical step for normal cells to acquire a TRAIL-sensitive phenotype during tumorigenesis and that the level of PP2A activity may foretell cellular sensitivity to TRAIL-induced apoptosis., Implications: Inhibition of PP2A is a key determinant in acquiring TRAIL sensitivity during tumorigenesis, with c-Fos/AP-1 as an essential mediator.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results